Employees: 73
Size Aclaris Therapeutics (ACRS) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $555M, the 2594th largest of 3,085 United States companies the cockpit tracks. Shares closed at $3.50 on 18 Nov 2026.
Performance Over six months the shares fell 22.7%, against -16.7% for the median peer and -2.2% for the United States market (cap-weighted) — 8th lowest of 19 in its peer set.
Growth Revenue fell 59.3% over the last twelve months (peer median +6.4%); the operating margin is -1,412.4% (peer median 6.8%).
Valuation It trades at 69.1× enterprise value to sales against a peer median of 5.0× (2nd most expensive of 19).
Capital Return on invested capital runs 141.7 points below its cost of capital (9.9% WACC).
Short interest Short interest is 7.3% of the free float (30 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $6.40M | $7.83M | $18.7M | $31.2M | $29.8M |
| Revenue growth | — | -58% | -40% | +5% | — |
| Gross profit | $370,000 | $542,000 | $3.46M | $13.2M | $17.8M |
| EBITDA | -$90.0M | -$73.4M | -$49.0M | -$114M | -$84.4M |
| Net income | -$79.6M | -$64.9M | -$132M | -$88.5M | -$86.9M |
| Free cash flow | -$75.3M | -$47.2M | -$20.2M | -$79.6M | -$68.2M |
| Capital expenditure | -$725,000 | $111,000 | $35.9M | $1.31M | $605,000 |
| Total debt | $1.71M | $2.12M | $2.60M | $3.50M | $2.25M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACRS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -7.2% | -11.4% | 8th highest of 20 |
| 6-month return | -22.7% | -16.7% | 8th lowest of 19 |
| Distance from 52-week high | -47.0% | -41.3% | 5th lowest of 20 |
| Revenue growth (TTM) | -59.3% | +6.4% | 4th lowest of 20 |
| Operating margin | -1,412.4% | 6.8% | 2nd lowest of 19 |
| EV / Sales | 69.1× | 5.0× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -141.7 pp | -2.5 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aclaris Therapeutics ACRS | United States | $555M | -23% | -59% | -1,412% | 69.1× | n/a | n/a |
| Boryung 003850.KS | South Korea | $554M | -13% | +6% | 6% | 0.9× | -3.1% | +12.6% |
| Tianjin Lisheng Pharmaceutical 002393.SZ | China | $557M | -24% | -3% | 7% | 1.2× | -5.8% | +4.1% |
| Zevra Therapeutics ZVRA | United States | $552M | -9% | +75% | 31% | 2.4× | -4.9% | +51.6% |
| Zeria Pharmaceutical 4559.T | Japan | $552M | -12% | +12% | 15% | 1.0× | -12.3% | +11.1% |
| Jinhe Biotechnology 002688.SZ | China | $550M | -19% | +7% | 5% | 1.8× | 1.0% | +9.7% |
| Zhong Zhu Healthcare 600568.SS | China | $562M | -22% | -6% | -34% | 6.2× | n/a | n/a |
| Jenkem Technology 688356.SS | China | $563M | -30% | +52% | 11% | 8.7× | 36.4% | +11.2% |
| Entera Bio ENTX | United States | $568M | +163% | -100% | n/a | n/a | n/a | n/a |
| Morepen Laboratories MOREPENLAB.NS | India | $542M | +121% | +30% | 11% | 2.2× | n/a | n/a |
| Alumis ALMS | United States | $569M | -80% | -67% | -5,375% | 23.9× | n/a | n/a |
| Senores Pharmaceuticals SENORES.NS | India | $538M | +3% | +40% | 24% | 7.4× | n/a | n/a |
| Beijing Tong Ren Tang Chinese Medicine 3613.HK | Hong Kong | $577M | -26% | -21% | 32% | 1.9× | -15.4% | +2.8% |
| Abbisko Cayman 2256.HK | Hong Kong | $578M | -39% | -83% | -520% | 20.1× | n/a | n/a |
| Chimin Health Management 603222.SS | China | $533M | -31% | +1% | -28% | 6.6× | n/a | n/a |
| Oneness Biotech 4743.TWO | Taiwan | $580M | -13% | +19% | -589% | 101.5× | n/a | n/a |
| Lepu Biopharma 2157.HK | Hong Kong | $580M | -43% | +47% | 7% | 4.5× | n/a | n/a |
| Electra Therapeutics ETRA | United States | $530M | n/a | n/a | n/a | n/a | n/a | n/a |
| Jinling Pharmaceutical 000919.SZ | China | $529M | -15% | -8% | 1% | 0.7× | 2.4% | +5.0% |
| Supriya Lifescience SUPRIYA.NS | India | $529M | -15% | +23% | 26% | 5.5× | 28.2% | +15.8% |
| Evonile Pharma EVONILE.NS | India | $529M | n/a | -5% | 12% | 16.2× | 49.3% | -1.5% |